RP Management LLC:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:RP Management LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10821
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
RP Management LLC (RP Management) is a life sciences financing company that offers biopharmaceutical products. The company’s products include thalomid, myozyme, lexiscan, rituxan, atripla, lyrica, prezista, letairis, januvia, onglyza, neupogen, rotateq, cubicin, savella, and others. It also provides nesina, remicade, humira, galvus, cimzia, mircera, tradjenta, viviant, Xtandi, tecfidera, imbruvica, and priligy. RP Management has interests in approved and late stage development bio-pharmaceutical products. The company offers its products in the therapeutic areas of rheumatoid arthritis (RA), chronic kidney disease, Crohn’s disease, diabetes, HIV/AIDS and others. It operates through research institutions, biotechnology and pharmaceutical companies, and inventors. RP Management is headquartered in New York, the US.

RP Management LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RP Management LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
RP Management LLC, Medical Devices Deals, 2012 to YTD 2018 9
RP Management LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RP Management LLC, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Royalty Pharma Acquires Royalty Streams and Milestones of Products from Zealand Pharma 11
Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 13
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 14
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 16
Royalty Pharma Acquires Royalties on Cystic Fibrosis Treatments from Cystic Fibrosis Foundation Therapeutics for USD3.3 Billion 18
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 20
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For US$510 Million 21
Royalty Pharma Acquires Ibrutinib Royalty Rights From Quest Diagnostics For US$485 Million 22
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 23
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For US$761 Million 25
Venture Financing 26
Avillion Secures Funds from Royalty Pharma 26
Private Equity 27
Aisling Capital And Clarus Ventures Acquire 20% Of Royalty Interest In Ibrutinib From Royalty Pharma 27
Equity Offering 28
Immunomedics to Raise USD75 Million in Private Placement of Shares 28
RP Management LLC – Key Competitors 30
RP Management LLC – Key Employees 31
RP Management LLC – Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
RP Management LLC, Pharmaceuticals & Healthcare, Key Facts 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RP Management LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RP Management LLC, Deals By Therapy Area, 2012 to YTD 2018 8
RP Management LLC, Medical Devices Deals, 2012 to YTD 2018 9
RP Management LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Royalty Pharma Acquires Royalty Streams and Milestones of Products from Zealand Pharma 11
Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 13
Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 14
Royalty Pharma Acquires Royalty Rights of Xtandi from University of California, Los Angeles for USD1.14 Billion 16
Royalty Pharma Acquires Royalties on Cystic Fibrosis Treatments from Cystic Fibrosis Foundation Therapeutics for USD3.3 Billion 18
Royalty Pharma Completes Acquisition of Royalties on Alogliptin and Priligy from Forest Labs for USD415 Million 20
Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For US$510 Million 21
Royalty Pharma Acquires Ibrutinib Royalty Rights From Quest Diagnostics For US$485 Million 22
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For US$25 Million 23
Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For US$761 Million 25
Avillion Secures Funds from Royalty Pharma 26
Aisling Capital And Clarus Ventures Acquire 20% Of Royalty Interest In Ibrutinib From Royalty Pharma 27
Immunomedics to Raise USD75 Million in Private Placement of Shares 28
RP Management LLC, Key Competitors 30
RP Management LLC, Key Employees 31

List of Figures
RP Management LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RP Management LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RP Management LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
RP Management LLC, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[RP Management LLC:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Abivax SA (ABVX):企業の財務・戦略的SWOT分析
    Summary Abivax SA (Abivax) operates as a biotechnology company. It develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to …
  • Vedanta Ltd:企業の戦略・SWOT・財務情報
    Vedanta Ltd - Strategy, SWOT and Corporate Finance Report Summary Vedanta Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Shire plc:企業のM&A・事業提携・投資動向
    Shire plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Shire plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Bassett Furniture Industries Inc (BSET):企業の財務・戦略的SWOT分析
    Bassett Furniture Industries Inc (BSET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Lexicon Pharmaceuticals Inc (LXRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program …
  • Regal Hotels International Holdings Ltd:企業の戦略・SWOT・財務情報
    Regal Hotels International Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Regal Hotels International Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • The Andersons Inc (ANDE):企業の財務・戦略的SWOT分析
    The Andersons Inc (ANDE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Falck Renewables SpA (FKR):企業の財務・戦略的SWOT分析
    Falck Renewables SpA (FKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Nippon Flour Mills Co., Ltd.:企業の戦略・SWOT・財務分析
    Nippon Flour Mills Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Flour Mills Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Argenx SE (ARGX):企業の財務・戦略的SWOT分析
    Summary Argenx SE (Argenx) is a human antibodies developer. The company offers autoimmunity and oncology products. Its wholly owned product candidates include ARGX-113, ARGX-110, ARGX-117 and ARGX-111. Argenx partnered product candidates are ARGX-109, ARGX-112, ARGX-115 AND ARGX-116. The company off …
  • Arcontech Group PLC (ARC):企業の財務・戦略的SWOT分析
    Summary Arcontech Group PLC (Arcontech), formerly Knowledge Technology Solutions PLC, is a technology company that provides real-time market data management solutions. The company provides products and bespoke systems for collection, processing, distribution and presentation of financial markets dat …
  • Abu Dhabi Commercial Bank PJSC:企業の戦略・SWOT・財務情報
    Abu Dhabi Commercial Bank PJSC - Strategy, SWOT and Corporate Finance Report Summary Abu Dhabi Commercial Bank PJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Birla Corporation Ltd:企業の戦略・SWOT・財務情報
    Birla Corporation Ltd - Strategy, SWOT and Corporate Finance Report Summary Birla Corporation Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Mahindra & Mahindra Limited:戦略・SWOT・企業財務分析
    Mahindra & Mahindra Limited - Strategy, SWOT and Corporate Finance Report Summary Mahindra & Mahindra Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Carillion plc:戦略・SWOT・企業財務分析
    Carillion plc - Strategy, SWOT and Corporate Finance Report Summary Carillion plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • A.G.Barr p.l.c.:企業の戦略・SWOT・財務情報
    A.G.Barr p.l.c. - Strategy, SWOT and Corporate Finance Report Summary A.G.Barr p.l.c. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Disco Corp (6146):企業の財務・戦略的SWOT分析
    Disco Corp (6146) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Expro Holdings UK 2 Limited:企業の戦略的SWOT分析
    Expro Holdings UK 2 Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Huber+Suhner AG (HUBN):企業の財務・戦略的SWOT分析
    Huber+Suhner AG (HUBN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • TelaDoc Inc (TDOC)-医療機器分野:企業M&A・提携分析
    Summary TelaDoc Inc (Teladoc) is a provider of telehealth services. The company offers short term prescription for amoxicillin, azithromycin, bactrim DS, augmentin, cipro, tessalon perles, flonase nasal spray, pyridium, prednisone and diflucan. It provides telehealth services for cold and flu sympto …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆